Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200711 | 0.95 | ADORA1 (0.51) | ADORA1ADORA3ADORA2ANPC1RAB9A | |
| SCHEMBL203119 | 0.83 | EDNRA (0.47) | NPC1RAB9AMEN1LMNAKMT2A | |
| SCHEMBL2260576 | 0.82 | CHEK2 (0.53) | ADORA1ADORA3ADORA2ANPC1RAB9A | |
| SCHEMBL201063 | 0.81 | GABRA1 (0.54) | ADORA1ADORA3ADORA2ANPC1RAB9A | |
| SCHEMBL2261442 | 0.81 | MCHR1 (0.59) | ADORA1ADORA3ADORA2ANPC1RAB9A | |
| SCHEMBL200964 | 0.80 | GABRA1 (0.54) | ADORA1ADORA3ADORA2ANPC1RAB9A | |
| SCHEMBL1690034 | 0.79 | CYP3A4 (0.61) | ADORA1ADORA3NPC1RAB9AMEN1 | |
| SCHEMBL2260303 | 0.79 | NPC1 (0.65) | ADORA1ADORA3ADORA2ANPC1RAB9A | |
| SCHEMBL2261168 | 0.79 | NPC1 (0.62) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2259263 | 0.78 | GABRA1 (0.53) | ADORA1ADORA3ADORA2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411358-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2010108856-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108856-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | ADORA1 1170/4885ADORA3 1120/4885ADORA2A 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.